Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DIG | 65.08 | 0.45 | +0.70% |
| ProShares Ultra Energy (DIG) | |||
| TELG | 13.91 | N/A | N/A |
| Leverage Shares 2X Long TEL Daily ETF (TELG) | |||
| DDTJ | 20.56 | -0.03 | -0.15% |
| Innovator Equity Dual Directional 10 Buffer ETF - January (DDTJ) | |||
| UOCT | 42.06 | -0.12 | -0.28% |
| Innovator U.S. Equity Ultra Buffer ETF - October (UOCT) | |||
| IMFL | 33.55 | -0.30 | -0.89% |
| Invesco International Developed Dynamic Multifactor ETF (IMFL) | |||
A.I.dvisor tells us that DXR and IART have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DXR and IART's prices will move in lockstep.
| Ticker / NAME | Correlation To DXR | 1D Price Change % | ||
|---|---|---|---|---|
| DXR | 100% | -1.49% | ||
| IART - DXR | 33% Poorly correlated | +1.11% | ||
| BWAY - DXR | 27% Poorly correlated | -8.33% | ||
| AVTR - DXR | 23% Poorly correlated | -2.14% | ||
| COO - DXR | 20% Poorly correlated | -0.56% | ||
| SHC - DXR | 20% Poorly correlated | -1.03% | ||
More | ||||
| Ticker / NAME | Correlation To DXR | 1D Price Change % |
|---|---|---|
| DXR | 100% | -1.49% |
| Pharmaceuticals: Other industry (49 stocks) | 5% Poorly correlated | +1.90% |
| Pharmaceuticals industry (151 stocks) | -9% Poorly correlated | +0.95% |
a provider of original medical equipment for medical personnel
Industry PharmaceuticalsOther
The RSI Indicator for DXR moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 19 similar instances when the indicator left oversold territory. In 15 of the 19 cases the stock moved higher. This puts the odds of a move higher at 79%.
Following a +3.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where DXR advanced for three days, in 141 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
DXR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
DXR moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DXR crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
The Aroon Indicator for DXR entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.952) is normal, around the industry mean (4.964). P/E Ratio (5.000) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (3.480) is also within normal values, averaging (4.143). Dividend Yield (0.014) settles around the average of (0.005) among similar stocks. P/S Ratio (8.389) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. DXR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.